top of page
Boston Medical Center

What's New?

Follow us
on LinkedIn and Instagram:
@SyndemicsLab

Funders & Collaborators

NIDA_edited_edited.jpg
723px-US_CDC_logo_edited.png
CFAR_formal_logo.png
pp2020-08-04_CHERISH LOGO_MAP_edited.png

Recent Publications

HIV, PrEP, Buprenorphine, Naloxone, Opioid Epidemic,

Prescriptions and Reimbursement of Glucagon Products for Severe Hypoglycemia in Medicaid

Noah M. Feder, Ryan O'Dea, Margaret Zupa, Jing Luo

HIV, PrEP, Buprenorphine, Naloxone, Opioid Epidemic,

Abatacept Pharmacokinetics and Exposure Response in Patients Hospitalized With COVID-19
A Secondary Analysis of the ACTIV-1 IM Randomized Clinical Trial

Stephen J. Balevic, Daniel K. Benjamin Jr, William G. Powderly, P. Brian Smith, Daniel Gonzalez, Matthew W. McCarthy, Linda K. Shaw, Christopher J. Lindsell, Sam Bozzette, Daphne Williams, Benjamin P. Linas, John Blamoun, Heta Javeri, Christoph P. Hornik, for the ACTIV-1 IM Study Group

HIV, PrEP, Buprenorphine, Naloxone, Opioid Epidemic,

Economic Evaluation of Extended-Release Buprenorphine for Persons With Opioid Use Disorder

Juliet M. Flam-Ross, Elizabeth Marsh, Michelle Weitz, Alexandra Savinkina, Bruce R. Schackman, Jianing Wang, R. W. M. Madushani, Jake R. Morgan, Joshua A. Barocas, Alexander Y. Walley, Stavroula A. Chrysanthopoulou, Benjamin P. Linas, Sabrina A. Assoumou

HIV, PrEP, Buprenorphine, Naloxone, Opioid Epidemic,

Estimating Absenteeism Related to Nonalcohol Substance Use in a US National Cohort of Full-Time Employees

Morgan JR, Murphy SM, Assoumou SA, Linas BP

HIV, PrEP, Buprenorphine, Naloxone, Opioid Epidemic,

Viral Hepatitis Elimination in Infants, Children, and Pregnancy: Elimination for Everyone by Everyone

Ravi Jhaveri, Rachel Epstein, Peyton Thompson

HIV, PrEP, Buprenorphine, Naloxone, Opioid Epidemic,

The association between naloxone claims and proportion of independent vs. chain pharmacies: A longitudinal analysis of naloxone claims in the US

Christina E. Freibott, Ali Jalali, Sean M. Murphy, Alexander Y. Walley, Benjamin P Linas, Philip J Jeng, Jeffrey Bratberg, Brandon D.L. Marshall, Xiao Zang, Traci C Green, Jake R. Morgan

HIV, PrEP, Buprenorphine, Naloxone, Opioid Epidemic,

Estimated Costs and Outcomes Associated With Use and Nonuse of Medications for Opioid Use Disorder During Incarceration and at Release in Massachusetts

Avik Chatterjee, Michelle Weitz, Alexandra Savinkina, Alexandria Macmadu, R. W. M. A. Madushani, Ruth A. Potee, Danielle Ryan, Sean M. Murphy, Alexander Y. Walley, Benjamin P. Linas,

HIV, PrEP, Buprenorphine, Naloxone, Opioid Epidemic,

Medicaid Hepatitis C Virus Treatment Policies: Impact on Testing and Treatment in the Commercially Insured

Epstein RL, Wang J, White LF, Kapadia SN, Morgan JR, Bao Y, Linas BP

HIV, PrEP, Buprenorphine, Naloxone, Opioid Epidemic,

Clinical- and Cost-Effectiveness of Liver Disease Staging in Hepatitis C Virus Infection: A Microsimulation Study

Rachel L Epstein, Sarah Munroe, Lynn E Taylor, Patrick R Duryea, Benjamin Buzzee, Tannishtha Pramanick, Jordan J Feld, Dimitri Baptiste, Matthew Carroll, Laurent Castera, Richard K Sterling, Aurielle Thomas, Philip A Chan, Benjamin P Linas

HIV, PrEP, Buprenorphine, Naloxone, Opioid Epidemic,

Test characteristics for combining non-invasive liver fibrosis staging modalities in individuals with Hepatitis C virus

Rachel L Epstein, Benjamin Buzzee, Laura F. White, Jordan J, Feld, Laurant Castera, Richard K. Sterling, Benjamin P. Linas, Lynn E. Taylor

HIV, PrEP, Buprenorphine, Naloxone, Opioid Epidemic,

Potential barriers to filling buprenorphine and naltrexone prescriptions among a retrospective cohort of individuals with opioid use disorder

Morgan JR, Quinn EK, Chaisson CE, Ciemins E, Stempniewicz N, White LF, Larochelle MR

HIV, PrEP, Buprenorphine, Naloxone, Opioid Epidemic,

Impact of prenatal substance use policies on commercially insured pregnant females with opioid use disorder

Tabatabaeepour N, Morgan JR, Jalali A, Kapadia SN, Meinhofer A

bottom of page